Drug intelligence / Profile preview

RMD-006

Development stage: Preclinical
Lead developer: Remedium Technologies
Modality: Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

RMD-006 is an experimental gene therapy being developed by Remedium Technologies for the treatment of ischemic stroke. It utilizes the company's proprietary Prometheus™ platform, which is designed to provide adjustable and dose-responsive gene expression. This platform aims to overcome the limitations of traditional gene therapies by allowing for the modulation or reversal of transgene expression. RMD-006 is delivered using either adeno-associated virus (AAV) or lipid nanoparticle (LNP) vectors. While the specific transgene or molecular target has not been publicly disclosed, the therapy is currently in the discovery and in vivo proof-of-concept stages of development.

Beyond the preview

Go deeper on RMD-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RMD-006.

Explore the full profile